SUNRISE, Fla., March 20 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) will report financial results for the year ended December 31, 2007 after the close of the market on Thursday, March 27, 2008. The Company has scheduled a conference call for Thursday, March 27, 2008 at 4:30 p.m. Eastern to discuss these results.
Interested parties can access the call by dialing (877) 858-9308 or (706) 643-0580, or can listen via a live Internet web cast, which can be found at http://www.bioheartinc.com. A replay of the call is available via webcast at http://www.bioheartinc.com for 30 days or by playback at (800) 642-1687 or (706) 645-9291 through March 29, 2008. Please use conference id #: 39978839 for the replay.
About Bioheart, Inc.:
Bioheart, Inc. is a biotechnology company focused on the discovery,
development and, subject to regulatory approval, commercialization of
autologous cell therapies for the treatment of chronic and acute heart
damage. Its lead product candidate, MyoCell(R), is an innovative clinical
cell therapy designed to populate regions of scar tissue within a patient's
heart with autologous muscle cells, or cells from the patient's body, for
the purpose of improving cardiac function in chronic heart failure
patients. The company's pipeline includes multiple product candidates for
the treatment of heart damage, including Bioheart Acute Cell Therapy, an
autologous, adipose cell treatment for acute heart damage, and MyoCell II
with SDF-1(TM), a therapy utilizing autologous cells genetically modified
to express additional growth factors.
MyoCell and MyoCell II with SDF-1 are registered trademarks of Bioheart, Inc.
Contact: William Kline Lytham Partners, LLC
Chief Financial Officer Joe Diaz
Nicholas Burke Joe Dorame
VP - Financial Operations Robert Blum
(954) 835-1500 (602) 889-9700
|SOURCE Bioheart, Inc.|
Copyright©2008 PR Newswire.
All rights reserved